The Industrial Biotechnology Leadership Forum newsletter

ETDE provides the engineering capabilities to guide SMEs through the “valley of death”

“ In addition to designing processing facilities including the Biorenewable Development Centre, ETDE use their expertise to help SMEs assess the

various commercial aspects of an idea”

Industrial Biotechnology Leadership Forum

Newsletter December 2012

Photo: the Biorenewables Development Centre

efficiency of biological drug production.

The profit from BioSyntha’s contract services is used to fund its own research in the industrial biotechnology field. BioSyntha is developing processes for the synthesis of platform chemicals, such as those used to make plastics, from renewable resources rather than petroleum feedstocks. Around the world there is a lot of R&D into the use of lignocellulosic biomass as a renewable resource that does not compete with the food/feed chain for synthesis of platform chemicals and fuel. However, commercial adoption is hindered by a number of factors including high enzyme cost and generation of inhibitors during processing. An alternative approach is gasification of biomass to generate Syngas (mainly carbon monoxide and hydrogen) which can act as a growth substrate for CO-utilising microorganisms. BioSyntha is involved in the development of such microorganisms capable of converting syngas to a range of useful chemicals by engineering their metabolic pathways to produce alternate chemicals to those they make in nature. The project has been partially funded by a Technology Strategy Board technical feasibility grant, which has been invaluable in helping BioSyntha to invest in the equipment, to develop the tools to work with these challenging anaerobic microorganisms and to file patent applications. As the project moves forward the company plans to work with the Centre for Process Innovation to develop larger scale fermentation methodology.

To move to the next stage the company recognises the value that could be added by collaboration with industry as well as with academia, and BioSyntha is working with the Knowledge Transfer Networks to take the business to the next level.

Ann Kramer, CEO of BioSyntha, says “One of the next big steps will be for us to work with academic partners to access their skills and technology to form bigger projects and industry partners to collaboratively develop new IP which can address bigger challenges than we can alone. It’s only really by joining forces in a larger network that we can compete on the global stage with the US and Europe.”

“We are working with the Chemistry Innovation and Biosciences KTNs to link into the right networks. We believe that is the route to large scale success in this area. We’ve done well to grow so quickly in tough times but to make the difference we want to, we need to find people with complementary expertise, and work together on solving the big international challenges.”

http://www.biosyntha.com

Capabilities on offer to customers include metabolic engineering as well as classical strain improvement to design and develop microorganisms, biocatalysis and fermentation. Whilst most current projects are still commercially sensitive, one successful project was with TMO Renewables, a company developing and commercialising integrated solutions to convert waste to energy.

The BioSyntha team, then under Novacta, worked with TMO to develop a strain of heat-stable bacterium which made ethanol as the sole fermentation product, with efficiency to rival that of yeast fermentation. TMO acquired the patent, the modified organism, and the tools to modify it further, and this technology is now at the core of their operations.

BioSyntha also provides services to the pharmaceutical industry through its microbial culture collection. For example, mammalian metabolites of drug candidates that are hard to produce chemically can be synthesised in a single step using microbes allowing for further metabolic or toxicity evaluation. The approach is readily scalable producing up to kilogram quantities of metabolite if required. BioSyntha can also improve biocatalytic and fermentation processes to improve the cost-

Joining forces with others will allow us to compete on the global stage, says CEO

BioSyntha Technology Ltd spun out of Novacta Biosystems earlier this year; bringing with it an experienced and capable team of scientists looking to provide research support to companies across biological and chemical industries. It has doubled in size in its first year and is now looking to expand through collaboration with business and academia.

BioSyntha’s foundations lie with Novacta’s industrial biotechnology contract research group who formed the new company at the start of 2012, operating out of the same lab with an experienced team. After years of pursuing a successful dual business model of contract research and proprietary biotherapeutic discovery, Novacta is now focused on development of its biopharmaceutical portfolio.

The new company offers a range of biotechnology services to customers, including technical expertise to solve biological challenges, providing a range of customers with the technology and in some cases, IP to advance their products.

02 www.IBLF-UK.com

Company News

BioSyntha Technology doubles size in first year and is looking to grow though collaboration

Photo of labs at BioSyntha Technology Ltd

dynamics for the team developing their IB engineering support. In addition to designing facilities that suit processing requirements, ETDE use their expertise to help SMEs assess the various commercial aspects of an idea:

“This involves everything from working out what investment they require to whether their manufacturing strategy fits their business model” says Mark Randle. “From working out these details, we can then present the best production routes for scaling up their product and safely guide businesses across the “valley of death” that can befall the commercialisation of research.”

ETDE is often connected with SME partners through networking opportunities provided by Chemistry Innovation and Biosciences KTNs. “The IBLF (Industrial Biotechnology Leadership Forum) events bring together organisations at each level of the development phase who are looking for partnering opportunities” says Mark. “As well as providing introductions between relevant parties, the KTNs also provide support as the partnership progresses, including identifying funding calls.”

As part of a project funded by the Technology Strategy Board, ETDE worked in a consortium alongside Protein Technologies Limited (PTL), Plymouth Marine Laboratory and University College London to improve downstream processing for large-scale biorefineres.

With the depletion of the earth’s hydrocarbon resources, scientists around the globe are working hard to develop sustainable bioprocesses for the production of fuels and platform chemicals essential to modern life. The consortium found evidence to suggest that the biggest technical stumbling

Engineering contractor helps companies understand the step-change from laboratory scale to the larger quantities that will produce profit

Manchester-based ETDE designs and builds engineering facilities for the advanced manufacturing sector. They partner with companies across the UK to develop technical engineering capabilities that enable organisations to scale up processes from the laboratory to commercial manufacture.

ETDE have completed design and construction work for many industrial and academic organisations working with industrial biotechnology. Recent projects include Croda’s industrial biotechnology facility at Widnes, The National Industrial Biotechnology Facility at the Centre For Process Innovation (CPI), Wilton and the Biorenewable Development Centre (BDC) based at York University.

The BDC brings together capabilities at two separate centres based at York (Centre for Novel Agricultural Products and the Green Chemistry Centre of Excellence) to offer joint biorenewable facilities. ETDE was tasked with developing processes and equipment that could optimise plants and microbes as feedstock at scales from 10-100 kg.

According to Mark Randle, Relationship Manager at ETDE, the partnership approach taken with the team at York is similar to ETDE’s work with all universities and multinational firms. “Each project starts with working out how to develop a facility that suits their processing requirements before progressing onto phases of the development, costings and logistics.”

SMEs currently present the biggest growth area for ETDE – creating new partnership

The Industrial Biotechnology Leadership Forum newsletter 03

ETDE provides the engineering capabilities to guide SMEs through the “valley of death”

block in the development of very large-scale biorefineries is not the molecular engineering of micro organisms that express these compounds, but rather their efficient downstream processing.

The vast majority of bioprocesses are undertaken on a batch basis however, conventional stirred tank reactor fermentation technology is unable to handle the massive volumes of low value products that a large scale biorefinery must process to function economically.

To address this, together with its partners ETDE built a continuous flow system that can be bolted onto front end systems. “This new system provides an economical way for organisations to improve their downstream processing for the very large scale bioprocessing of cellular matter” says Mark. “The system was built and in operation within six months – a hugely successful project for all partners involved.”

www.etde.co.uk

“The IBLF (Industrial Biotechnology Leadership Forum) events bring together organisations at each level of the development phase who are looking for partnering opportunities”

Photo: Croda’s industrial biotechnology facility at Widnes

The future for enzyme development

Industrial biotechnology is driving innovation in enzyme development – and the best is yet to come, says Stuart West, Managing Director of Biocatalysts

The UK has a strong foundation in fermentation and biosciences that is recognised across the world. As Managing Director of Biocatalysts, an enzyme manufacturing company that uses fermentation to develop our products – 80% of which are exported abroad – I’m passionate about promoting UK capabilities in this field.

Biocatalysts supplies enzymes primarily to the food processing market, helping to make their manufacturing processes more efficient. What does this translate to on your supermarket shelves? The baking industry relies on enzymes to create a uniform shape for muffins, whilst leading condiment brands depend on enzymes to modify the egg yolk in their mayonnaise to increase its shelf-life.

Industrial biotechnology has been a key driver of change in enzyme production over the past ten years. Previously, enzyme development was a slow and costly process, open to only large manufacturers developing bulk products for big markets. Advances in modern genetics, including gene sequencing and access to enzyme databases, have

the past five years, such as the cost of genome sequencing falling faster than Moore’s Law, have rapidly increased knowledge and commercial application opportunities in this area. To secure UK capabilities, Osborne announced that BBSRC is investing £20 million into leading universities and researchers in the UK to use synthetic biology to benefit the UK economy by addressing major global challenges, such as producing low-carbon fuel and reducing the cost of industrial raw materials.

Opportunities for academia and industry to engage with synthetic biology will form another key element of Leading IB: A UK Showcase, an event hosted by the IBLF to demonstrate success stories in industrial biotechnology. Alongside key speakers discussing how they have harnessed biotechnology for commercial success, the event will also provide an opportunity to expand upon the UK strategy for 2015 to ensure that academic and industrial activities continue to grow in this space. This debate will be stimulated by a report from Jonathan Porritt that coincides with the Showcase and examines the ways in which industrial biotechnology can solve developing global issues and drive innovation in established industries.

Porritt’s report portrays a balanced picture of opportunities and risk to the general public in understandable terms. This “decoding of the science” is important in securing greater support from government, policy makers, NGOs, investors and the public at large. We will therefore pass a number of important milestones as we enter the new year, building ever greater momentum.

Ian Shott CBE, Industry Chairman

04 www.IBLF-UK.com

IBLF News

As we look towards the start of 2013, industrial biotechnology is gaining momentum across UK academia and industry. Recently, I was at Newcastle University presenting a lecture to members of their Engineering Doctorate in Biopharmaceutical Process Development. This programme is one of a series of its kind that have been funded by EPSRC as an alternative to the traditional PhD for students who want a year in industry. The course at Newcastle is run by the university’s Biopharmaceutical Bioprocessing Technology Centre (BBTC). A number of other UK universities are also developing similar programmes.

At the lecture it was encouraging to see a wide cross section of industry members, from start-up companies to large multi-nationals, each showing a vested interest in realising the opportunities for their business in industrial biotechnology. Bringing developing biotechnologies into and out of education and academia is a key step that will enable the UK to access growing global markets – a view that is endorsed by policy makers. In a speech at the Royal Society, George Osborne recently outlined the government’s long-term programme for investing in British Science.

The Chancellor focused on the importance of bridging the gap between scientific discovery and industrial commercialisation to secure future UK economic and social development. Osborne identified eight future technologies where the UK has potential to be world-leading – one of these being synthetic biology, which has a global market that is predicted to grow in value to £11 billion by 2016.

Advances in synthetic biology over

Industrial Biotechnology – gaining momentum with academia, industry and policy makers

Ian Shott CBE, Industry Chairman

Leading IB: A UK ShowcaseThe Industrial Biotechnology Leadership Forum invites business leaders, academics and policy makers from the UK and across the EU to showcase success in industrial biotechnology and bio-based products

The global bioeconomy is gaining pace and the UK is positioning itself at the forefront. The IBLF is hosting the Leading IB: A UK Showcase event to illustrate the advances that have been made in exploiting industrial biotechnology in the UK and progress that can be made in future.

The two-day event will be opened by Michael Fallon, Minister of State for Business and Enterprise and will reflect on the projects and processes that have enabled the UK to achieve success in the sector. These successes will be highlighted in the IB Done Well report – written by Jonathan Porritt, Founder Director of Forum for the Future and commissioned by the IBLF – which will be launched at the event.

The event will include presentations by key speakers including Ian Shott, Chair of the IBLF who will be discussing the UK strategy for industrial biotechnology; Joanna Dupont-Inglis will be providing an EU policy perspective from EuropaBio; and Ian Fotheringham will be sharing Ingenza’s experiences of becoming a worldwide leader in the application of

now radically reduced the time and cost implications for enzyme processing and created new opportunities for the commercial world.

Organisations working in enzyme development can now create bespoke enzymes on a much smaller scale, using a streamlined process that has been reduced from a year to a matter of weeks. These advances have opened the world of enzyme technology to a much wider range of companies and industries that can now afford to have enzymes developed for a specific process.

These discoveries have been pioneered by academic bases at UK universities and research centres, with the government playing an increasingly integral role in turning these discoveries into tangible commercial offerings. The Technology Strategy Board has provided significant investment in the National Industrial Biotechnology Facility (NIBF) at CPI, and further supported its use in the High Value Chemicals through Industrial Biotechnology Competitions. This facility enables companies to scale up fermentation processes to ensure they work on more significant levels before committing capital investment.

The Leading IB: A UK Showcase event will highlight even more opportunities for industry to engage with the latest enzyme processes that are being pioneered using industrial biotechnology. If you were to develop a custom enzyme using current processes it would take around six weeks – in a few years, this will be a matter of days. Industry will soon be able to use computer simulation to design enzymes and change their structure to achieve a desired effect or property in the end product. This is currently achieved through mutation and long, expensive screening processes, however, within the next three to five years, in silico design will be fast become the standardised way of modifying enzyme structure.

Organisations like the Biosciences KTN and the Industrial Biotechnology Leadership Forum can support and create links between parties at each stage of the latest development process: from universities to manufacturers and industry. The new technologies to transform an organisation’s productivity and revenue through industrial biotechnology are about to arrive – make sure you aren’t left behind.

Stuart West is Managing Director of Biocatalysts and is a speaker at Leading IB: A UK Showcasehttp://www.biocatalysts.com

The Industrial Biotechnology Leadership Forum newsletter 05

industrial biotechnology and synthetic biology.

Attendees will be invited to hear from senior industrialists and stakeholders as part of a panel discussion that will consider the IB landscape beyond 2015 and opportunities for UK industry.

The final plenary session will focus on science and innovation and the event will be finish with a key note presentation from David Willetts, Minister of State for Universities and Science on The Technology and Innovation Landscape.

The event will inspire new manufacturers to explore IB potential and build collaborations through an exhibition that is also taking place. Exhibitors include Croda, Cellucomp, EPSRC and the Centre for Process Innovation, each showcasing their success in IB process and products. Exhibitors will act as a source of advice and inspiration for companies looking to exploit their potential in the sector.

Chemistry Innovation and Bioscience KTNs will be supporting the event by providing information on funding opportunities and facilities for UK organisations, in addition to coordinating a 1-to-1 partnering programme that will enable delegates to find new collaborative partnerships.

More information can be found at www.iblf-uk.com/showcase2013

Leading IB: A UK Showcase is taking place Tuesday 22nd – Wednesday 23rd January 2013, Church House Conference Centre, Westminster, London

Photo from the Leading IB: Focus on Biocatalysis event

to bring together a large consortium of partners to explore replacements to traditional petrochemical feedstocks and move towards more sustainable, environmentally friendly processes” says Dr. Malone. “Chemistry Innovation KTN is one of our partners and supports crucial dissemination of this work to the wider scientific community.”

Another large project is the recently launched €26.6 million CHEM21 consortium, funded by the Innovative Medicines Initiative. CHEM21 is jointly led by the University of Manchester and GlaxoSmithKline and has a remit of developing new sustainable catalytic technologies for the manufacture of active pharmaceutical ingredients (APIs).

Alongside engagement with industry and research communities, the MIB is increasingly active in public engagement and education outreach. Their researchers regularly interact with local schools and colleges, demonstrating practical biotechnology experiments with the aim of increasing awareness and understanding of science and how it impacts the general public.

As well as reaching out to local schools, the MIB hosts students in their laboratories as part of the Nuffield Bursary Placement

of activity, largely focused on proof of concept studies. “The programme has been well-received by industry and we are already getting demands for our next phase of activities” says Dr. Kirk Malone, Scientific Project Manager at CoEBio3. “This initiative provides the opportunity for companies to work in collaboration with Universities to pioneer breakthroughs in their sector, where otherwise it may not be feasible alone.”

CoEBio3 also has an outstanding track record of obtaining research funding from the European Union’s FP7-KBBE programme – the framework tasked with building a knowledge-based bioeconomy. Dr. Kirk Malone is responsible for one of CoEBio3’s biggest projects: BIONEXGEN, which is the largest funded project in the FP7-KBBE sector. This flagship €10.6 million collaborative R&D project involves 17 university and industrial partners across Europe and is focused on developing the next generation of biocatalysts to create eco-efficient manufacturing processes for the chemical industry. By building such scientific consortia and managing large EU projects, CoEBio3 has become a key player in a virtual centre for European Biotechnology, currently coordinating five large FP7-funded projects.

“BIONEXGEN provides the ideal platform

The North West Nucleus for BiotechnologyThe relaunch of the Manchester Institute of Biotechnology brings together the University’s activities across European collaborative R&D projects, industrial partnerships and public engagement.

In 2006 the University of Manchester opened the Manchester Interdisciplinary Biocentre as the UK’s first university-based, purpose-built interdisciplinary research institute focusing on biotechnology. The centre was relaunched this autumn as the Manchester Institute of Biotechnology (MIB) reflecting their renowned expertise in this area; spanning European biocatalysis projects, industrial biotechnology research and synthetic biology programmes.

The Institute sits at an inter-disciplinary level, drawing on expertise from across the University’s academic departments including biology, chemistry and physics. The MIB is also home to the Centre of Excellence for Biocatalysis, Biotransformations and Biocatalytic Manufacture (CoEBio3), the UK’s leading centre for applied biotechnology. CoEBio3 provides a world-class scientific environment to develop biocatalyst-based processes, and functions as a hub and spoke model to tap into key research institutes across the UK, including the Universities of York and Strathclyde. CoEBio3 sits at the interface of academia and industry, and one way it interacts with industry is through an affiliates programme. Industrial partners pay a fee to join the programme with all resources pooled towards industrially-relevant research, such as sponsoring PhD students or research associates. The benefits for industrial partners include joint access to research discoveries, novel biocatalysts and IP. The affiliates programme has completed two phases 06 www.IBLF-UK.com

Academic News

Photo: Manchester Institute of Biotechnology (MIB)

European opportunities:Bioenergy Sustaining the Future (BESTF) ERANET

Bioenergy demonstrations of the European Industrial Bioenergy Initiative

A consortium of eight EU Member States and Associated Countries, including the UK, Denmark, Finland, Germany, Portugal, Spain, Sweden and Switzerland, is implementing BESTF ERANET. This activity will provide funding to industry-led, collaborative bioenergy projects that demonstrate at least one innovative step and will result in demonstration at a pre-commercial stage.

Business Support for InnovationThe following schemes provide opportunities for businesses to engage with on-going projects, access new sources of funding and help influence industrial policy across the UK and Europe. Chemistry Innovation and the Biosciences KTNs offer free assistance to businesses at any stage of innovation, from initial briefing to market success.

UK Opportunities:£10 million available for R&D projects in enabling technologies

The Technology Strategy Board has announced up to £10 million of funding for collaborative R&D projects that stimulate innovation across four key enabling technology areas. The competition is seeking proposals that build on the development of a recent technological discovery by tackling an identifiable risk that could eventually solve a wide range of market opportunities and needs. The two key areas of interest for the IB community include:

1. Advanced materials, for example:• Nanotechnology-enabled materials

and functionality• Materials with reduced environmental

impact (including packaging materials)

• Bio-based materials

2. Biosciences, for example:• Formulation and delivery approaches

for biological products including biopharmaceuticals and functional foods

• Commercial application of sequencing technologies focusing on genomics

• Novel manufacturing processes for producing biological products and novel biological production systems

The Industrial Biotechnology Leadership Forum newsletter 07

Business Support

Scheme. This scheme invites students to spend a summer period working in laboratories on a research project. “The best way to inspire the next generation of research scientists is with hands-on, practical experience” says Dr. Malone. “The benefit for the Institute is ensuring that Manchester continues to enjoy a supply of innovative and skilled biotechnology talent.”

In line with the rest of the biotechnology community, the future for the MIB will have a strong focus on synthetic biology. George Osborne’s announcement of government’s long-term programme for investing in British Science focused on synthetic biology as one of eight future technologies where the UK has potential to be world-leading. The University of Manchester recently received funding from the BBSRC as part of the plan to drive development in this field and access a global market that is predicted to grow in value to £11 billion by 2016.

Professor Nicholas Turner, Director of CoEBio3, has recently been awarded £4.4million from the BBSRC to work on identifying biological alternatives to chemicals that are currently derived from fossil fuels. The funding adds to a £500,000 grant from the pharmaceutical company GlaxoSmithKline which will be working in collaboration with Professor Turner.

The researchers will develop a new approach to engineering robust biocatalysts by mimicking the process of evolution in the laboratory. This new platform technology will enable the optimisation of enzymes for industrial applications in a matter of weeks rather than the months which it currently takes.

www.mib.ac.uk

For more information contact: Dr Kirk Malone, Scientific Project Manager, CoEBio3 kirk.malone@manchester.ac.uk www.coebio3.org

Professor Nicholas Turner will be presenting at ‘The Leading IB: A UK Showcase’ event

08 www.IBLF-UK.com

Events EU’s Seventh Framework Programme for Research (FP7)

The European Commission has announced a €8.1 billion euro package of calls for proposals under the EU’s Seventh Framework Programme for Research (FP7). This is the final and largest ever package of FP7 calls, and is an important part of the Commission’s commitment to work for growth and jobs in Europe.

FP7 UK Food, Agri, Fisheries, Biotech

This funding call will allocate up to €1.9 billion over the duration of FP7 to building a knowledge-based bioeconomy (KBBE). The aim is to encourage science and industry to exploit new and emerging research across the food, feed, forest, fisheries, agriculture, aquaculture and chemistry sectors in order to address social, environmental and economic challenges.

The following areas are eligible to apply for funding:

KBBE.2013.3.1-01: Plant high value products – from discovery to final productKBBE.2013.3.2-02: The CO2 algae biorefinery. (There are already several organisations in the UK and in Ireland looking for partners)KBBE.2013.3.3-01: Support for demonstrating the potential of biotechnology applicationsKBBE.2013.3.3-02: Bioeconomy and bioregionsKBBE.2013.3.3-03: Opening markets for bio-based products: Standardisation, labelling and procurementKBBE.2013.3.3-04: Optimal and cost-effective industrial biocatalysis(There are already several organisations in the UK and in Ireland looking for partners)KBBE.2013.3.4-01: Preventing and valorising bio-waste in biorefineriesKBBE.2013.3.6-01: Novel bio-inspired materials and processesKBBE.2013.3.6-2: Synthetic biology towards applications

Next steps: any organisations looking for project partners, contact michelle.carter@biosciencektn.com

For more information: https://connect.innovateuk.org/web/fp7uk-food-agri-fisheries-biotech

BESTF funds will support demonstration projects in one or more of these seven value chains:

• Synthetic liquid fuels and/or hydrocarbons and blending components via gasification

• Bio-methane and other synthetic gaseous fuels from biomass via gasification

• High-efficiency heat and power generation via gasification of biomass

• Bioenergy carriers via other thermochemical processes (e.g. pyrolysis, torrefaction)

• Ethanol and higher alcohols from lignocellulosic feedstock via fermentation

• Renewable hydrocarbons through biological and/or chemical synthesis from biomass containing carbohydrates

• Bioenergy carriers from CO2 and sunlight through microorganism-based production and upgrading into fuels and valuable bio-products

UK Participation in BESTF

The Department of Energy and Climate Change, Biotechnology and Biological Sciences Research Council and the Technology Strategy Board have allocated a budget of up to €8 million to fund eligible UK industry and academic applicants.

Key dates

Competition opens: December 2012Webinar briefing: 12th December 2012Stage 1 submission deadline: March 2013Stage 2 submission deadline: August 2012

For more information: http://www.innovateuk.org/deliveringinnovation/internationalprogramme/bestf-eranet.ashx

Leading IB: A UK Showcase22-23rd January 2013, Westminster, London

A 2-day event showcasing new UK products and processes made possible through industrial biotechnology.

The global bioeconomy is gaining pace and the UK is positioning itself at the forefront. Illustrating the progress made in exploiting industrial biotechnology in the UK, the event will provide delegates with the opportunity to see recent examples of success, meet new collaborators, gain understanding of available facilities and find routes to access public and private finance.

Michael Fallon MP, Minister of State for Business and Enterprise at BIS, will open this event which will attract business leaders, technology providers, investors, leading academics and policy makers from the UK and across the EU.

More information and registration details can be found here: www.IBLF-UK.com/showcase2013

6th Annual Next Generation BiofuelsTue 05 -Thu 07 Feb 2013, Radisson Blu Falconer Hotel, Copenhagen

Selecting the right feedstocks, business models and technologies to accelerate the transition to biofuels from non-food crops

http://nextgenbiofuels.agraevents.com

Innovate UK: the UK’s largest innovation and trade eventMon 11 - Wed 13 Mar 2013, Business Design Centre, London

Innovate UK is the leading networking, conference and exhibition event for businesses to meet other businesses, Government and academia with the aim of making innovation and trade happen – creating opportunity and growth for the future.

https://connect.innovateuk.org/web/innovate

21st EU Biomass Conference & ExhibitionMon 03 - Fri 07 Jun 2013, Bella Center, Copenhagen

The European Biomass Conference aims to “bring together biomass experts from many countries, to provide a good picture of the most recent advances in research, development and application of biomass technologies for energy production”. It provides a high-level scientific programme and parallel events which attracts participants from a wide ranging background: Researchers, engineers, technologists, standards organisations, financing institutions and more.

http://www.conference-biomass.com/About-EU-BC-E.1064.0.html